Activated Partial Thromboplastin Time

Activated Partial Thromboplastin Time, or aPTT, is a blood-coagulation measure that provides a time-based view of how quickly coagulation occurs. The result is expressed in seconds, helping characterize the time involved in this part of the body’s clotting process.

Activated Partial Thromboplastin Time is measured from a plasma sample and reported in seconds. The result represents a time-based clotting measurement, so the sample must be collected and processed in a way that allows the laboratory to measure that interval consistently.

Fasting is not required for this test. When arranging testing, follow the laboratory’s instructions for providing the sample and share relevant information with the clinician or laboratory so the result can be considered alongside the reference and optimal ranges shown on the page. Related clotting assessments may also be considered when interpreting the result, depending on the clinical context.

An Activated Partial Thromboplastin Time result should be interpreted against the reference range printed on the same report. A result within that range is generally considered within the laboratory’s reference interval, while the optimal range is a narrower interval within the reference range. These ranges provide context for reading the number; the value is not meaningful in isolation from the range and unit shown on the report.

A single Activated Partial Thromboplastin Time value is not a diagnosis. Results outside the stated reference range should be discussed with a clinician, who can interpret the finding in the context of the individual and the reason the test was performed. The sample used for this measurement is plasma, and fasting is not required.

Activated Partial Thromboplastin Time (APTT) is expressed in seconds, and the desired result is a range rather than simply a higher or lower value. Changes therefore need to be interpreted in context, especially when assessing whether a movement remains within the appropriate range.

Among interventions measured directly, Omega-3 is recorded as decreasing APTT. However, the reported finding describes significantly higher APTT in the n-3 PUFAs group than in the placebo group, so the direction should be read alongside the study result rather than in isolation. Spirulina and Chamomile were unchanged in the direct trials that assessed them.

Rechecking has typically occurred after 1 to 12 weeks. These findings describe measured changes in APTT under specific study conditions and do not establish that an intervention should be used to alter it. A clinician can help interpret an APTT result when a medical condition or treatment is involved.